London Allergy & Immunology Centre
Clinical Immunology Assessment
Comprehensive evaluation of humoral and cellular immunity, including CVID diagnostic work-up, complement pathway assessment, IgG subclass analysis, and vaccine antibody responses — in line with current ESID, BSACI and IUIS guidelines (2024–2026).
What is Clinical Immunology?
Clinical immunology is the subspecialty concerned with the diagnosis and management of disorders arising from dysfunction of the immune system. These include primary immunodeficiency disorders (PIDs), complement deficiencies, autoimmune conditions, and hypersensitivity diseases. The London Allergy & Immunology Centre (LAIC) offers a structured, evidence-based assessment pathway for patients with suspected immunodeficiency, recurrent infection, or unexplained immune dysregulation.
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary antibody deficiency in adults, characterised by impaired antibody production arising from defects in B‑cell differentiation, often accompanied by T‑cell and complement abnormalities.[1] Diagnosis requires exclusion of secondary causes, demonstration of significant hypogammaglobulinaemia, poor vaccine antibody responses, and onset after the age of two years.
⚠︎ Important Vaccine Schedule Update — UK 2025–2026
Menitorix® (Hib/MenC) discontinued: GSK has ceased manufacture of Menitorix. From 1 July 2025, children turning one year of age on or after 1 July 2024 are no longer offered this vaccine as part of the routine UK childhood schedule. The JCVI confirmed that a replacement MenC dose in the infant schedule is not recommended, given herd immunity maintained by the adolescent MenACWY programme. An additional fourth dose of hexavalent DTaP/IPV/Hib/HepB vaccine is now offered at the new 18‑month appointment.[2,3] Hib/MenC is no longer expected to be in UK circulation after April 2026.[4]
Pneumovax 23 (PPV23) — transition to conjugate vaccines: Pneumovax 23 remains available but 20‑valent conjugate vaccine Prevenar 20 (formerly Apexxnar, PCV20) is increasingly preferred for immunocompromised adults, providing T‑cell dependent immunological memory unlike the polysaccharide vaccine.[5,6]
Clinical implication: When assessing specific antibody responses in patients with suspected immunodeficiency, the vaccine platform used (polysaccharide vs. conjugate) must be documented, as it profoundly affects expected antibody response kinetics, magnitude, and duration.
CVID Diagnostic Work-Up: Overview
The LAIC follows a systematic, tiered approach to immunological assessment, aligned with ESID/PAGID criteria and the CVID ICON 2015 consensus guidelines. Assessment is organised across four interconnected domains:
|
1. Humoral Immunity Serum immunoglobulins (IgG, IgM, IgA, IgE), IgG subclasses (IgG1–IgG4), specific antibody responses to vaccine antigens and natural infections. |
2. Cellular Immunity Lymphocyte subset analysis by flow cytometry: T cells (CD3, CD4, CD8), B cells (CD19, CD20), NK cells (CD16/CD56), with CD4:CD8 ratio. |
|
3. Complement Pathway Classical pathway (CH50, C3, C4), lectin pathway (MBL), alternative pathway (AH50 where indicated), and complement regulatory proteins. |
4. Vaccine Antibody Responses Functional antibody assessment post‑vaccination: MenB, MenACWY, pneumococcus, tetanus, Haemophilus, diphtheria; neoantigen challenges where applicable. |
1
Humoral Immunity Assessment
Humoral immunity is mediated by B‑lymphocytes and the antibodies they produce. Quantitative and qualitative assessment of serum immunoglobulins is the cornerstone of CVID diagnosis. Per ESID/CVID ICON 2015 criteria, a serum IgG level more than two standard deviations below the age-adjusted mean (typically <7–8 g/L in adults) is required, alongside reduced IgA and/or IgM in the majority of cases.[7]
Serum Immunoglobulins & IgG Subclasses
| Analyte | Role | Adult Reference | Clinical Significance |
|---|---|---|---|
| IgG | Primary antibody of secondary immune response; opsonisation, neutralisation, complement activation | 6.0–16.0 g/L | Principal diagnostic criterion for CVID. Values must be confirmed on at least two occasions ≥12 weeks apart. |
| IgG1 | ~70% of total IgG; primary responses to protein antigens and most vaccines | 4.9–11.4 g/L | Deficiency associated with recurrent sinopulmonary infections. Isolated IgG1 deficiency is uncommon but clinically significant. |
| IgG2 | Responses to polysaccharide antigens (encapsulated bacteria: pneumococcus, meningococcus, Hib) | 1.5–6.4 g/L | Most common IgG subclass deficiency. Strongly associated with poor responses to polysaccharide vaccines (PPV23). Children rely on conjugate vaccines (T‑dependent) to generate adequate anti-polysaccharide immunity. |
| IgG3 | Responses to viral antigens; potent complement activation | 0.20–1.10 g/L | Recognised as an important biomarker of humoral immune defect in updated CVID criteria.[7] Associated with susceptibility to recurrent viral upper respiratory tract infections. |
| IgG4 | Blocking antibody; allergen tolerance; elevated in IgG4‑related disease | 0.08–1.40 g/L | Isolated IgG4 deficiency rarely symptomatic alone. Markedly elevated IgG4 (>1.35 g/L) may indicate IgG4‑related systemic disease requiring specialist assessment. |
| IgA | Mucosal immunity; dominant antibody class in secretions (gut, airways, genitourinary tract) | 0.80–4.00 g/L | Selective IgA deficiency (sIgAD, <0.07 g/L) is the most common PID (1 in 600). Low IgA with low IgG supports CVID. Must test for anti-IgA antibodies before administering IVIG, due to anaphylaxis risk. |
| IgM | Primary antibody response; efficient complement activator; isohaemagglutinins | 0.40–2.30 g/L | Isolated low IgM raises suspicion of Hyper‑IgM syndrome (CD40L/CD40/AID defects). Absent isohaemagglutinins are an alternative functional criterion in CVID where IgM is low. |
| IgE | Allergic responses; mast cell and basophil activation; anti‑parasitic immunity | <100 kU/L | Markedly elevated total IgE (>2,000 kU/L) with recurrent infections may indicate Hyper‑IgE syndrome (STAT3 or DOCK8 mutations). IgE measurement assists in differentiating atopy from primary immunodeficiency. |
Reference ranges are laboratory-specific and age-dependent. All LAIC reports are interpreted against validated laboratory reference intervals.
2
Cellular Immunity & Lymphocyte Subset Analysis
Lymphocyte subset quantification by flow cytometry provides an essential cellular framework for characterising immune deficiency. CD19 and CD20 are the most widely used pan‑B‑cell markers, whilst T‑cell subsets and NK cells are defined by CD3, CD4, CD8, CD16, and CD56.[8] Immunophenotyping resources for these markers are available through BioLegend Immunology.
T Lymphocytes (Cellular / Adaptive Immunity)
| Marker | Cell Population | Adult Range | Clinical Relevance | BioLegend |
|---|---|---|---|---|
| CD3 | All T lymphocytes (pan‑T marker); forms signalling complex with TCR | 900–2,800/µL | Low CD3 indicates T‑cell lymphopaenia. Absent in SCID; severely reduced in DiGeorge syndrome. CD3 expression confirms T‑lineage identity. | Anti-CD3 |
| CD4 | T helper cells (Th1, Th2, Th17, Th22, T‑regulatory); essential for B‑cell maturation and antibody class‑switching | 500–1,500/µL; ratio 1.5–2.5 | CD4+ T helper cells are required for B‑cell maturation and class‑switching. Reduced CD4 count is characteristic of HIV and combined immunodeficiency. CVID patients may have reduced memory CD4 cells. CD4:CD8 ratio <1.0 warrants investigation for HIV. | Anti-CD4 |
| CD8 | Cytotoxic T lymphocytes (CTL); suppress viral replication; tumour surveillance | 200–900/µL | CD8+ CTLs mediate viral clearance. Expanded CD8 populations may indicate chronic viral infection (EBV, CMV) or immune dysregulation. CD8 T‑cell subsets (CD56+CD8+ NKT‑like cells) may be elevated in CVID patients with immune dysregulation. | Anti-CD8a |
B Lymphocytes (Humoral / Antibody-Mediated Immunity)
| Marker | Cell Population | Adult Range | Clinical Relevance | BioLegend |
|---|---|---|---|---|
| CD19 | Pan‑B cell marker (naive, memory, transitional, plasmablasts); co‑receptor complex with CD21/CD81 | 100–500/µL (6–19%) | Most widely used pan‑B‑cell marker. Markedly reduced or absent (<2%) in X‑linked agammaglobulinaemia (XLA/BTK deficiency). CD19 monogenic mutations produce CVID‑like disorder excluding true CVID diagnosis.[7] Memory subsets (CD19+CD27+) are critical for B‑cell maturation staging in CVID.[8] | Anti-CD19 |
| CD20 | Mature B cells (excluding plasma cells); expressed from pre‑B through memory B‑cell stages | Overlaps with CD19+ | Complementary B‑cell marker and therapeutic target for anti-CD20 biologics (rituximab, obinutuzumab). CD20 absent on plasma cells; essential for monitoring B‑cell depletion therapy efficacy and recovery. Rare CD20 mutations produce CVID‑like phenotype. | Anti-CD20 |
Natural Killer (NK) Cells (Innate Lymphoid Immunity)
| Marker Combination | NK Subset | Adult Range | Clinical Relevance |
|---|---|---|---|
| CD16+CD56+ (CD3−) |
CD56dimCD16+ — cytotoxic NK cells (predominant peripheral blood subset) | 90–600/µL total NK; 7–22% of lymphocytes |
NK cells (CD3−CD16+CD56+) provide innate cytotoxicity against virally‑infected and malignant cells. Identified as CD3− to distinguish from NKT cells. Absent NK cells (X‑linked SCID) indicate combined immunodeficiency. NK cell deficiency predisposes to severe herpesvirus infections (CMV, EBV, VZV).[9] |
| CD56brightCD16− | Regulatory / cytokine‑producing NK cells (minor peripheral subset) | <10% of total NK | CD56bright NK cells produce IFN‑γ and TNF‑α; involved in immune regulation. CD56bright and CD56dim NK subsets both decline with age.[9] |
Full lymphocyte immunophenotyping panels, reagents and gating guidance: BioLegend Immunology
3
Complement Pathway Assessment
Complement is a family of over 30 circulating and membrane‑bound proteins that bridge innate and adaptive immunity. Three activation pathways — classical, lectin (MBL), and alternative — converge at C3 and culminate in the membrane attack complex (MAC, C5b–C9). Complement deficiencies predispose patients to recurrent encapsulated bacterial infections, particularly meningococcal disease.[10]
| Test | Pathway | Reference | Interpretation & Clinical Significance |
|---|---|---|---|
| CH50 / CH100 | Classical (C1q, C4, C2, C3, C5–C9) | 70–180 U/mL | Best screening assay for classical pathway deficiency. Absent CH50 (<10%) with normal C3/C4 indicates terminal complement deficiency (C5–C9) and severe susceptibility to meningococcal disease. Low CH50 with low C3 and C4 suggests consumption. Note: eculizumab / ravulizumab therapy suppresses CH50 to undetectable levels.[11] |
| C3 | Central convergence point of all three pathways | 0.90–1.80 g/L | C3 deficiency confers susceptibility to encapsulated bacteria (pneumococcus, meningococcus) and immune complex disease. Low C3 with low C4: classical pathway consumption (SLE, cryoglobulinaemia). Isolated low C3 with normal C4: alternative pathway over‑activation or C3 nephritic factor. |
| C4 | Classical & lectin pathways | 0.16–0.47 g/L | C4 null alleles (C4A and C4B) are common and produce persistently low C4 without active consumption. Complete C4 deficiency is strongly associated with SLE‑like disease and recurrent pyogenic infections. Interpret alongside C3 and C4 gene copy number. |
| MBL (Mannose-Binding Lectin) |
Lectin pathway (MBL‑MASP activation; C2–C9) | >200 ng/mL; >10% functional activity | MBL is a liver‑derived pattern recognition protein of innate immunity. It binds bacterial carbohydrates (mannose, GlcNAc, fucose) and activates complement by forming a complex with MASP‑1 and MASP‑2, which cleave C4 and C2 to form the C3 convertase.[12] MBL deficiency (MBL2 polymorphisms, prevalence 5–30%) is associated with susceptibility to recurrent respiratory infections. Isolated MBL deficiency is confirmed when CH50, C3, and C4 are normal but MBL functional activity is <10%.[11] Clinical significance is greatest when MBL deficiency co‑exists with other immunological defects. |
4
Specific Antibody Responses to Vaccines and Common Infections
Quantitative immunoglobulin levels alone do not establish functional humoral immunity. Assessment of specific antibody responses — to T‑independent (polysaccharide) and T‑dependent (protein conjugate) antigens — is critical to confirm CVID and to assess susceptibility to encapsulated pathogens. Poor or absent vaccine responses are a diagnostic requirement for CVID under all current criteria.
Meningococcal Antibody Assessment
| Antigen / Vaccine | Assay | Protective Threshold | Clinical Notes (2025–2026) |
|---|---|---|---|
| MenACWY (Nimenrix / Menveo) |
Serum bactericidal antibody (SBA) or anti‑capsular IgG ELISA (serogroups A, C, W, Y) | SBA ≥1:4 (human complement); IgG ≥0.5 µg/mL per serogroup | MenACWY conjugate generates a T‑cell‑dependent response. Following Menitorix withdrawal (July 2025), herd protection against MenC in infants is sustained by the adolescent MenACWY programme. For immunodeficient patients without herd protection, direct vaccination and post‑vaccination antibody assessment (4–6 weeks) is recommended.[2,4] |
| MenB (Bexsero / Trumenba) |
hSBA against reference strains (44/76‑SL, 5/99, NZ98/254); anti‑NHBA, anti‑fHbp, anti‑NadA IgG | hSBA ≥1:4 against reference strains | MenB vaccine (Bexsero) uses protein surface antigens (fHbp, NHBA, NadA, PorA PVL45), not polysaccharides, making it particularly suitable for patients with IgG2 subclass deficiency. Response is T‑cell dependent. Immunocompromised patients, especially those with complement deficiency, are at high risk of meningococcal disease and should receive MenB vaccination with serological confirmation of response. |
Additional Specific Antibody Responses
| Antigen | Antibody Measured | Purpose | Notes |
|---|---|---|---|
| Pneumococcus | Anti‑capsular IgG (WHO serotype panel: 3, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) | Assess T‑independent (PPV23) and T‑dependent (PCV20) antibody responses; evaluate IgG2 function | Standard neoantigen challenge for CVID. PPV23 (Pneumovax 23) elicits T‑cell‑independent response with no immunological memory. PCV20 (Prevenar 20/Apexxnar) confers T‑cell‑dependent memory and is increasingly preferred in high‑risk groups.[5,6] Pre‑ and post‑vaccination levels (4 weeks post‑vaccination) are measured; a protective response requires ≥1.3 µg/mL in ≥70% of serotypes tested. |
| Tetanus toxoid | Anti‑tetanus IgG (ELISA) | T‑dependent (protein antigen) response; gold standard for B‑cell/T‑cell co‑operation | Protective level >0.1 IU/mL. Absent response after documented booster (Td‑IPV) is strong evidence of impaired T‑dependent humoral immunity. |
| Haemophilus influenzae b (Hib) | Anti‑PRP IgG (polyribosylribitol phosphate) | T‑dependent conjugate antibody response to encapsulated bacterium | Protective level ≥0.15 µg/mL; long‑term protection ≥1.0 µg/mL. Relevant in context of Menitorix schedule changes; absent Hib antibody following documented vaccination is highly informative.[2,3] |
| Diphtheria | Anti‑diphtheria IgG (ELISA or Vero cell neutralisation) | T‑dependent protein antigen response | Protective: ≥0.01 IU/mL basic; >0.1 IU/mL good protection. Absence after documented vaccination strongly supports humoral immune defect. |
| Varicella‑Zoster Virus (VZV) | Anti‑VZV IgG | Confirm prior immunity; guide antiviral prophylaxis | VZV susceptibility in immunodeficiency carries risk of disseminated infection. Absent antibody in unvaccinated patients may necessitate passive immunisation (VZIG) post‑exposure. |
| EBV | Anti‑VCA IgG, anti‑EBNA IgG, anti‑EA IgG; EBV PCR where indicated | Characterise EBV immunity; detect reactivation and lymphoproliferation | EBV infection can unmask or precipitate CVID‑like features and drive lymphoproliferation. EBV serology differentiates primary infection from reactivation. |
| CMV | Anti‑CMV IgG/IgM; CMV PCR (if clinically indicated) | Assess prior exposure and immunity status | CMV seronegativity is relevant before HSCT and IVIG product selection. CMV viraemia in T‑cell immunodeficiency requires specialist antiviral management. |
CVID Diagnostic Pathway: Step‑by‑Step
The following pathway reflects current ESID/PAGID and CVID ICON 2015 diagnostic criteria, adapted for clinical use at LAIC.
|
1
|
Clinical Suspicion & History Recurrent sinopulmonary infections (≥2 pneumonias in 3 years, ≥4 sinusitis episodes per year), persistent or atypical infections, bronchiectasis, autoimmune phenomena, unexplained lymphoproliferation, gastrointestinal complications, onset after age 2 years, family history of immunodeficiency. |
|
2
|
First‑Line Investigations • Full blood count (FBC) with differential lymphocyte count • Serum immunoglobulins: IgG, IgA, IgM, IgE • IgG subclasses: IgG1, IgG2, IgG3, IgG4 • Lymphocyte subsets: CD3, CD4, CD8, CD19, CD20, CD16/CD56 • Complement: C3, C4, CH50 • Specific antibodies: anti‑tetanus, anti‑pneumococcal (serotype panel), anti‑Hib, anti‑diphtheria • Exclude secondary causes: protein‑losing enteropathy (albumin, faecal alpha‑1 antitrypsin), nephrotic syndrome (urine protein), iatrogenic (rituximab, anti‑epileptics, mycophenolate) › Criterion: IgG confirmed <7–8 g/L on at least two occasions ≥12 weeks apart, onset after age 2 years.[7] |
|
3
|
Vaccine Antibody Challenge Where specific antibody levels are subprotective and prior vaccination is uncertain, a controlled challenge is performed: • MenACWY conjugate (Nimenrix or Menveo) — T‑cell‑dependent response; now primary meningococcal conjugate for immunodeficient patients following Menitorix withdrawal[2] • MenB (Bexsero) — protein antigen vaccine; T‑cell dependent; particularly indicated in complement deficiency • Pneumococcal: Prevenar 20 (PCV20) preferred; Pneumovax 23 (PPV23) for polysaccharide response assessment[5,6] • Tetanus/diphtheria booster (Td‑IPV) — gold standard T‑dependent protein challenge › Measure specific antibodies 4–6 weeks post‑vaccination. Failure to reach protective thresholds or mount a ≥2‑fold rise fulfils CVID functional diagnostic criteria. |
|
4
|
Extended Complement & Innate Immunity Panel • MBL functional activity — confirms lectin pathway deficiency when <10% with normal CH50 and C3/C4[11,12] • AH50 (alternative pathway) — indicated in recurrent Neisserial infection or isolated low C3 with normal C4 • C1q, C2 levels — in SLE‑like features with absent CH50 • Complement regulatory proteins (Factor H, Factor I) — in aHUS or C3 glomerulopathy |
|
5
|
Advanced B‑Cell Immunophenotyping (where CVID confirmed or likely) • Memory B cells (CD19+CD27+): switched memory (IgM−CD27+) and non‑switched (IgM+CD27+) • Transitional B cells (CD19+CD38++CD24++) • Plasmablasts (CD19+CD38+++CD27+) › Impaired switched memory B cells (<2% of total B cells) are the most consistent CVID finding and constitute a Category C diagnostic criterion.[7] Measured on at least two occasions, as values may vary. |
|
6
|
Multidisciplinary Review, Genetic Counselling & Treatment Plan Results are reviewed in full clinical context. Monogenic CVID‑like disorders (NFKB1, NFKB2, LRBA, CTLA4, PIK3CD, RAC2, CARD11, etc.) are excluded where appropriate, as these are categorically distinct from CVID.[7,13] Management includes immunoglobulin replacement (IVIG or SCIG), antimicrobial prophylaxis, vaccination strategy (live vaccines are contraindicated in confirmed CVID), and organ‑specific surveillance (pulmonary CT, gastroscopy, lymphoma screening). |
Our Clinical Immunology Consultants
Dr Hilary Longhurst & Prof Michael Rudenko — Consultants in Clinical Immunology & Allergy
Dr Longhurst and Prof Rudenko are GMC‑registered Consultants Immunologists with extensive experience in adult primary immunodeficiency disorders, including CVID, hereditary angioedema (HAE), complement deficiencies, and immune dysregulation syndromes. They provide specialist assessment, diagnosis, and long‑term management of complex immunological conditions at LAIC.
When to Refer for Immunological Assessment
Referral to a clinical immunologist should be considered in adults or children presenting with any of the following warning signs (Jeffrey Modell Foundation / BSACI guidance):
|
› ≥4 ear infections per year (children) or ≥2 per year (adults)
› ≥2 pneumonias in any 12‑month period
› Recurrent deep skin or organ abscesses
› Bronchiectasis without identifiable aetiology
› Need for intravenous antibiotics to clear infection
|
› Invasive meningococcal disease, especially recurrent
› Unexplained low immunoglobulins on routine testing
› Autoimmune cytopaenia (ITP, AIHA, neutropaenia)
› Recurrent angioedema without urticaria (suspect HAE)
› Family history of primary immunodeficiency
|
References & Further Reading
- Bonilla FA et al. (2025, updated). Common Variable Immunodeficiency. StatPearls [NCBI Bookshelf NBK549787]. Last updated November 2025.
- UK Government / DHSC (2025). Changes to the Routine Childhood Vaccination Schedule from 1 July 2025 and 1 January 2026. gov.uk. April 2025.
- JCVI (2022). Interim Statement on the Immunisation Schedule for Children following Menitorix Discontinuation. Published 5 August 2022. gov.uk.
- UKHSA (2025). Hib/MenC PGD v6.0. Valid 1 July 2025 – 30 April 2026. NHS England.
- European Medicines Agency (2024–2025). Prevenar 20 (previously Apexxnar) EPAR. ema.europa.eu. Updated November 2025.
- Fleet Street Clinic (2026). Pneumonia Vaccination for Children & Adults. Updated February 2026. fleetstreetclinic.com.
- Ameratunga R et al. (2013, 2016); Picard C et al. (2015). New and updated diagnostic criteria for CVID / CVID ICON 2015. Clin Exp Immunol 174:203–211; JACI In Practice 2016.
- Leblé T et al. (2024). Diagnostic tests for primary immunodeficiency disorders: classic and genetic testing. PMC11425801.
- Mitričeski G et al. (2020). Comprehensive flow cytometric reference intervals of leukocyte subsets from six European study centres. Clin Exp Immunol 202:363.
- Walport MJ (2001). Complement. N Engl J Med 344:1058–1066 & 1140–1144.
- Mayo Clinic Laboratories (2024). MBLF – Mannan Binding Lectin Complement Pathway, Functional, Serum. mayocliniclabs.com.
- Eisen DP (2010). Mannose‑Binding Lectin Deficiency and Respiratory Tract Infection. PMC7179718.
- Mistry A et al. (2024). Key Flow Cytometry Markers Assessed Across Multiple Disease Categories. mlm‑labs.com.
London Allergy & Immunology Centre — Harley Street, Est. 2011
Book your Immunology Assessment Today
Consultations available at Harley Street and across London. No GP referral required for self‑pay patients. Appointments typically available within one week.